Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction

J Clin Psychopharmacol. 2005 Feb;25(1):89-91. doi: 10.1097/01.jcp.0000150234.99619.f3.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / pharmacokinetics*
  • Antipsychotic Agents / therapeutic use
  • Biotransformation
  • Cytochrome P-450 CYP2D6 / genetics
  • Cytochrome P-450 CYP2D6 / metabolism
  • Drug Interactions
  • Female
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Psychiatric Status Rating Scales
  • Risperidone / pharmacokinetics*
  • Risperidone / therapeutic use
  • Schizophrenia / drug therapy
  • Schizophrenia / genetics
  • Thioridazine / adverse effects*
  • Thioridazine / therapeutic use

Substances

  • Antipsychotic Agents
  • Cytochrome P-450 CYP2D6
  • Risperidone
  • Thioridazine